ANDA 75697, held by Baxter Hlthcare Corp. Butorphanol Tartrate.
As of Nov 16, 2026, ANDA 75697 (Butorphanol Tartrate), held by Baxter Hlthcare Corp, was first approved by FDA on Oct 23, 2001, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 23, 2001 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Butorphanol Tartrate2MG/ML · injectable;injection | Butorphanol Tartrate | Discontinued |
| Oct 11, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jun 12, 2008 | Supplement 12Manufacturing | Approved | None posted |
| Oct 23, 2001 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters